Sarepta Therapeutics Inc. (SRPT) Given “Outperform” Rating at Oppenheimer Holdings Inc.
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reissued by equities researchers at Oppenheimer Holdings Inc. in a report released on Monday. They presently have a $76.00 price target on the stock. Oppenheimer Holdings Inc.’s target price would suggest a potential upside of 55.29% from the stock’s current price.
Other research analysts have also issued reports about the company. Needham & Company LLC increased their price objective on Sarepta Therapeutics from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, July 22nd. Janney Montgomery Scott upgraded Sarepta Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $30.00 to $65.00 in a report on Monday, September 19th. Piper Jaffray Cos. set a $68.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 4th. Vetr upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating and set a $17.28 target price on the stock in a report on Monday, June 20th. Finally, Jefferies Group upgraded Sarepta Therapeutics from an “underperform” rating to a “hold” rating and set a $50.00 target price on the stock in a report on Monday, September 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $63.31.
Sarepta Therapeutics (NASDAQ:SRPT) traded down 6.39% during midday trading on Monday, reaching $48.94. 4,715,756 shares of the company traded hands. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The company has a 50-day moving average price of $45.66 and a 200-day moving average price of $26.92. The company’s market cap is $2.34 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the business posted ($0.87) earnings per share. On average, analysts predict that Sarepta Therapeutics will post ($4.23) earnings per share for the current fiscal year.
In other news, CEO Edward M. Md Kaye sold 24,352 shares of the business’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $1,217,600.00. Following the completion of the transaction, the chief executive officer now owns 89,983 shares of the company’s stock, valued at approximately $4,499,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Teacher Retirement System of Texas boosted its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new stake in Sarepta Therapeutics during the second quarter worth approximately $154,000. Quantitative Systematic Strategies LLC bought a new stake in Sarepta Therapeutics during the second quarter worth approximately $211,000. BNP Paribas Arbitrage SA raised its stake in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares during the period. Finally, National Planning Corp raised its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. 65.06% of the stock is owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.